- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Therapeutic Areas
- Oncology
- Publications
- Programs
- Pipeline
- mTORC1/2 inhibitor Sapanisertib
- SYK Inhibitor Mivavotinib
- Preclinical Programs
- Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
- Discovery Discor
- Pre-ind Pre-ind Pre-ind
- Ph1 Phase 1
- Ph2 Phase 2
- Ph3 Phase 3
- Discor
- Discor
- Pre-IND
- Ph2
- Pre-IND
Programs
Calithera Pipeline
Targeted, biomarker-defined small molecules Targeted, biomarker-defined
small moleculesSynthetic Lethality Target VPS4A:VPS4B mutated solid tumorsSynthetic Lethality Targets: UndisclosedAdditional Small Molecule ProgramsCB-668 IL4I1 InhibitorImmuno-Oncology‘1158* Arginase InhibitorImmuno-OncologyCB-708* CD-73 InhibitorImmuno-Oncology*Partnered program
Clinical Trials
We are advancing our pipeline with a new approach
to fighting cancer and other life-threatening diseases.